Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-in-human clinical trial of Intravitreal LSC Exosome Therapy Age-Related Macular Degeneration (AMD).

Next Previous
Trial Profile

First-in-human clinical trial of Intravitreal LSC Exosome Therapy Age-Related Macular Degeneration (AMD).

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Limbal-stem-cell-exosome-therapeutics-YD-Bio-Limited (Primary)
  • Indications Age-related macular degeneration
  • Focus Adverse reactions; First in man

Most Recent Events

  • 12 Jan 2026 New trial record
  • 05 Jan 2026 According to YD Bio limited media release, the company is planning Completion of preliminary preclinical studies; Initiation and conclusion of efficacy and toxicity studies; and IND submission to the U.S. FDA. in 2026.Trial is expected to initiate in 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top